
ADRO
Healthcare · Biotechnology · $236.6M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2020
EPS trend, 90 days to now · -300.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 3, 2020 | Time not confirmed | -0.95 | -1.05 | -10.5% |
| May 4, 2020 | Time not confirmed | -0.67 | -0.45 | +32.8% |
| Mar 9, 2020 | Time not confirmed | -1.05 | -1.20 | -14.3% |
| Nov 7, 2019 | Time not confirmed | -1.16 | -1.30 | -12.1% |
| Aug 1, 2019 | Time not confirmed | -0.91 | -1.15 | -26.4% |
| May 7, 2019 | Time not confirmed | -0.95 | -1.45 | -52.6% |
| Feb 27, 2019 | Time not confirmed | -1.16 | -1.65 | -42.2% |
| Oct 30, 2018 | Time not confirmed | -1.56 | -1.45 | +7.1% |
| Aug 1, 2018 | Time not confirmed | -0.32 | -0.31 | +3.1% |
| May 2, 2018 | Time not confirmed | -0.35 | -0.28 | +20.0% |
| Mar 1, 2018 | Time not confirmed | -0.36 | -0.34 | +5.6% |
Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with…